Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 12,643 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period A Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm

NCT01236768
View directory record Official record
Conditions
Contraception
Interventions
AG200-15, Levora
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
21
States / cities
Mobile, Alabama • Green Valley, Arizona • Tucson, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Nov 4, 2026, 10:20 AM EST
Terminated Phase 4 Interventional

Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease

NCT01832350
View directory record Official record
Conditions
Alzheimer's Disease, Pseudobulbar Affect (PBA)
Interventions
Nuedexta (20/10)
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
55 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Nov 4, 2026, 10:20 AM EST
Completed Not applicable Interventional Results available

Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia

NCT01963676
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Auditory Hallucinations
Interventions
tDCS, Sham stimulation
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Nov 4, 2026, 10:20 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Diet & Activity Community Trial: High-Risk Inflammation

NCT01760902
View directory record Official record
Conditions
Inflammation
Interventions
Diet and Physical Activity
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
30 Years and older
Enrollment
438 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Nov 4, 2026, 10:20 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Gene Expression Correlates of Post-Traumatic Stress Disorder (PTSD) Symptom Change After EFT (Emotional Freedom Techniques)

NCT01250431
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
EFT (Emotional Freedom Techniques)
Behavioral
Lead sponsor
Soul Medicine Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
Santa Rosa, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Nov 4, 2026, 10:20 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

NCT00988429
View directory record Official record
Conditions
Partial Epilepsy
Interventions
800 mg QD Eslicarbazepine acetate, 1200 mg QD Eslicarbazepine acetate, Placebo
Drug
Lead sponsor
Bial - Portela C S.A.
Industry
Eligibility
16 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
106
States / cities
Mobile, Alabama • Northport, Alabama • Phoenix, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Nov 4, 2026, 10:20 AM EST
Completed Not applicable Interventional

Evaluating the Feasibility, Acceptability, and Preliminary Outcomes of Heart Rate Variability Biofeedback for Individuals With Opioid Use Disorder.

NCT07361731
View directory record Official record
Conditions
Autonomic Nervous System Imbalance, Heart Rate Variability (HRV), Opioid Use Disorder, Breathing Techniques, Opioid Craving, Recovery, Emotional Regulation, Positive and Negative Affect, Stress, Biofeedback
Interventions
Heart rate variability biofeedback
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Nov 4, 2026, 10:20 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Open-Label, Multi-Center, Clinical Study Evaluating the Effect of the NDE L68 StableFit® Punctal Plug on the Tear Lake

NCT04280653
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
NDE L68 StableFit® Punctal Plug
Device
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Edgewood, Kentucky • Garden City, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Nov 4, 2026, 10:20 AM EST
Recruiting Phase 1Phase 2 Interventional

Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

NCT06194929
View directory record Official record
Conditions
Cutaneous Melanoma, Brain Metastases
Interventions
Defactinib, Avutometinib, Encorafenib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Iowa City, Iowa • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Nov 4, 2026, 10:20 AM EST
Completed Not applicable Interventional

Evaluation of a Test Algorithm for Use to Analyze ECG Data Collected From a Test Device of a 24-hour Simulated Use Period

NCT07188129
View directory record Official record
Conditions
Atrial Fibrillation (AF), Tachycardia, Bradycardia, PVC - Premature Ventricular Contraction, Premature Atrial Contraction
Interventions
Test Algorithm and Test Device
Device
Lead sponsor
Zywie, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Nov 4, 2026, 10:20 AM EST
Completed Phase 3 Interventional Results available

Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy

NCT00419341
View directory record Official record
Conditions
Primary Immune Deficiency
Interventions
Human Normal Immunoglobulin for Subcutaneous Administration
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
2 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Nov 4, 2026, 10:20 AM EST
Completed Not applicable Interventional Results available

Evaluation of an Incentive-based Intervention to Improve 90-day Adherence in PAP-Naive Patients

NCT03851094
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Wellth app
Behavioral
Lead sponsor
ResMed
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Nov 4, 2026, 10:20 AM EST
Completed Phase 3 Interventional Results available

Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction.

NCT02836899
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Nitric Oxide, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Nov 4, 2026, 10:20 AM EST
Completed Phase 3 Interventional Results available

A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis

NCT00048932
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Double-blind Abatacept, Double-blind Placebo, Open-label Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
44
States / cities
Decatur, Alabama • Paradise, Arizona • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2011 · Synced Nov 4, 2026, 10:20 AM EST
Withdrawn Early Phase 1 Interventional

Effect of Kava on Anxiety and Stress in Cancer Survivors

NCT06213298
View directory record Official record
Conditions
Kava, Anxiety, Stress, Cancer, Depression, Sleep
Interventions
Kava, Placebo
Drug · Dietary Supplement
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 4, 2026, 10:20 AM EST
Terminated Phase 3 Interventional Results available

LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

NCT03711929
View directory record Official record
Conditions
Non Infectious Uveitis
Interventions
DE-109 Intravitreal Injections, Sham Procedure, DE-109 Intravitreal Injections (Open Label)
Drug · Other
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
38
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Nov 4, 2026, 10:20 AM EST
Completed Phase 3 Interventional Results available

Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy

NCT03179631
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Disease, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
Interventions
Ataluren, PLACEBO
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
5 Years and older · Male only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Nov 4, 2026, 10:20 AM EST
Completed Phase 2 Interventional Results available

Nuedexta in Treatment-Resistant Major Depression

NCT01882829
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant
Interventions
dextromethorphan/quinidine
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Nov 4, 2026, 10:20 AM EST
Completed Phase 3 Interventional Results available

TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

NCT03745651
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Fremont, California • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Nov 4, 2026, 10:20 AM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

NCT02316353
View directory record Official record
Conditions
Hereditary Angioedema Types I and II
Interventions
C1-esterase inhibitor
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
6 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Nov 4, 2026, 10:20 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating Blood Concentrations Of Rosuvastatin When Co-administered With GW856553 In Healthy Men

NCT00549653
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease
Interventions
GW856553
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Nov 4, 2026, 10:20 AM EST
Recruiting Not applicable Interventional

Comparing Acupuncture vs. Sham Acupuncture for the Management of Hot Flashes in Prostate Cancer Patients Receiving Hormone Therapy

NCT07594002
View directory record Official record
Conditions
Accupuncture, Prostate Cancer, Hormone Therapy, Hot Flashes
Interventions
Real Acupuncture, Sham Acupuncture
Device
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Nov 4, 2026, 10:20 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effects on Bioavailability of MDMA in Healthy Volunteers

NCT05147402
View directory record Official record
Conditions
Pharmacokinetics
Interventions
midomafetamine
Drug
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Nov 4, 2026, 10:20 AM EST
Enrolling by invitation Not applicable Interventional

TMS Pilot in Early AD II

NCT06817902
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Intermittent theta burst stimulation active coil, Sham coil
Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
40 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Nov 4, 2026, 10:20 AM EST